Home / Resource Library / Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3‑Year Follow‑up of the Belgian Ibrutinib Real‑World Data (BiRD) Study

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3‑Year Follow‑up of the Belgian Ibrutinib Real‑World Data (BiRD) Study

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3‑Year Follow‑up of the Belgian Ibrutinib Real‑World Data (BiRD) Study